Chronic kidney disease (CKD), affecting 10–12% of the world’s adult population, is associated with a considerably elevated risk of serious comorbidities, in particular, premature vascular disease and death. Although a wide spectrum of causative factors has been identified and/or suggested, there is still a large gap of knowledge regarding the underlying mechanisms and the complexity of the CKD phenotype. Epigenetic factors, which calibrate the genetic code, are emerging as important players in the CKD-associated pathophysiology. In this article, we review some of the current knowledge on epigenetic modifications and aspects on their role in the perturbed uraemic milieu, as well as the prospect of applying epigenotype-based diagnostics and preventive and therapeutic tools of clinical relevance to CKD patients. The practical realization of such a paradigm will require that researchers apply a holistic approach, including the full spectrum of the epigenetic landscape as well as the variability between and within tissues in the uraemic milieu.
Skip Nav Destination
Article navigation
July 2017
-
Cover Image
Cover Image
This issue of Clinical Science showcases review articles covering kidney disease, the respiratory system, neurology and oxidative stress.
Review Article|
June 30 2017
Current epigenetic aspects the clinical kidney researcher should embrace
Anna Witasp;
Anna Witasp
1Division of Renal Medicine, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden
2Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden
Search for other works by this author on:
Amaryllis H. Van Craenenbroeck;
Amaryllis H. Van Craenenbroeck
1Division of Renal Medicine, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden
3Department of Nephrology, Antwerp University Hospital, University of Antwerp, Antwerp, Belgium
Search for other works by this author on:
Paul G. Shiels;
Paul G. Shiels
4Institute of Cancer Sciences, MVLS, University of Glasgow, Scotland, U.K.
Search for other works by this author on:
Tomas J. Ekström;
Tomas J. Ekström
2Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden
5Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
Search for other works by this author on:
Peter Stenvinkel;
1Division of Renal Medicine, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden
Correspondence: Peter Stenvinkel (peter.stenvinkel@ki.se)
Search for other works by this author on:
Louise Nordfors
Louise Nordfors
1Division of Renal Medicine, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden
2Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden
6Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
December 09 2016
Revision Received:
April 17 2017
Accepted:
April 19 2017
Online ISSN: 1470-8736
Print ISSN: 0143-5221
© 2017 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society
2017
Clin Sci (Lond) (2017) 131 (14): 1649–1667.
Article history
Received:
December 09 2016
Revision Received:
April 17 2017
Accepted:
April 19 2017
Citation
Anna Witasp, Amaryllis H. Van Craenenbroeck, Paul G. Shiels, Tomas J. Ekström, Peter Stenvinkel, Louise Nordfors; Current epigenetic aspects the clinical kidney researcher should embrace. Clin Sci (Lond) 15 July 2017; 131 (14): 1649–1667. doi: https://doi.org/10.1042/CS20160596
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Captcha Validation Error. Please try again.